Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Etanercept Liquid · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Etanercept Liquid | DRUG | - |
Inclusion Criteria: - Fulfill the 1987 American Rheumatism Association (ARA) criteria for RA - Active RA at the time of enrollment, receipt of concomitant methotrexate at a dose of up to 25 mg a week is permitted - Screening lab results must demonstrate: * AST and ALT less than or equal to 2 times ...
Top 20 of 31 competitors
Etanercept Liquid is being developed for the treatment of rheumatoid arthritis, an inflammatory joint disease. It is an investigational therapy that has been studied in adults with active rheumatoid arthritis. The clinical program has focused on this immunology indication.
Etanercept Liquid targets tumor necrosis factor, commonly known as TNF. It is classified as a TNF inhibitor. By targeting TNF, the drug is designed to interfere with a key inflammatory signaling molecule involved in rheumatoid arthritis.
Etanercept Liquid is being developed by Amgen Inc., which trades on Nasdaq under the ticker AMGN. Amgen is the sponsor of the clinical program for this investigational rheumatoid arthritis therapy.
Etanercept Liquid is in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 3 program for rheumatoid arthritis has completed one trial.
Etanercept Liquid has been studied in a Phase 3 trial, NCT00110903, titled Treatment for Subjects With Active Rheumatoid Arthritis (RA). The trial enrolled adults aged 18 years and older and has been completed. It was an uncontrolled study.